Quantcast

Latest Organofluorides Stories

2014-05-30 08:25:01

- 7 total abstracts accepted for afatinib and other compounds from the company's oncology research program RIDGEFIELD, Conn., May 30, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif® (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 - June 3, 2014. Data include...

2014-05-27 23:02:45

The Firm has filed a number of Risperdal lawsuits in the Pennsylvania proceeding on behalf of clients who allegedly developed gynecomastia (male breast growth) due to their use of Risperdal. New York, New York (PRWEB) May 27, 2014 As Risperdal lawsuits (http://www.injurybeacon.com/risperdal/lawsuit/) continue to mount in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP notes that the defense is seeking partial summary judgment...

2014-05-27 04:20:05

Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion...

2014-05-26 23:01:07

The Firm is currently offering free and confidential Lipitor lawsuit evaluations to individuals who may have developed Type 2 diabetes after taking the cholesterol-lowering statin. New York, NY (PRWEB) May 26, 2014 More than 230 Lipitor lawsuit (http://www.thelipitorlawsuit.com/) filings have been added to a federal litigation established in South Carolina since court documents were last updated in April, Bernstein Liebhard LLP reports. A Case List issued May 15th by the U.S. Judicial on...

2014-05-22 23:13:01

Recent motions in Pennsylvania courts mark progress for Risperdal gynecomastia lawsuits; Risperdal lawyers offer no-obligation Risperdal gynecomastia lawsuit case review. St. Louis, MO (PRWEB) May 22, 2014 Attorneys handling national Risperdal lawsuits for The Onder Law Firm report progress in the Risperdal lawsuits filed in Pennsylvania’s Complex Litigation Center. According to court documents*, a Motion for Summary Judgment regarding Statute of Limitations was filed earlier this...

2014-05-21 12:16:10

IQWiG Added benefit based on fewer side effects / no data for adolescents and pretreated adults who do not require integrase inhibitors Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality...

2014-05-20 12:33:19

Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is...

2014-05-14 23:07:18

This research report categorizes the global market for polyvinylidene fluoride on the basis of applications, end-user industries, and geography along with forecasting volume, value, and analyzing trends in each of the submarkets.(http://www.marketsandmarkets.com/Market-Reports/polyvinylidene-fluoride-pvdf-market-6146031.html) (PRWEB) May 14, 2014 According to a new market research report “Polyvinylidene Fluoride (PVDF) Market by End User Industry (Chemical Processing, Construction, New...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-14 20:23:28

-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR exon 19 deletion mutation RIDGEFIELD, Conn., May 14, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related